2 Best Pharma Stocks to Buy in November
Investors often chase the latest fads. In healthcare, the race to develop a vaccine for the novel coronavirus has certainly captured a significant share of Wall Street's attention this year. Small companies making big promises may capture headlines, but established pharmaceutical companies with histories of creating blockbuster drugs and robust pipelines of new candidates are often the wiser bet. The positive vaccine results reported yesterday by Pfizer (NYSE: PFE) and partner BioNTech (NASDAQ: BNTX) would seem to bolster the argument.
Two stand out this month as representing the best of both worlds -- companies with both solid drug-development track records and potential COVID-19 vaccine tailwinds that could net them each significant profits for their role over the next several years.
Image source: Getty Images
Source Fool.com
